Maria Carell resigns as President and CEO of Q-Med
Carina Bolin appointed as interim Chief Executive Officer
11-Mar-2011
- Sweden
Maria Carell is resigning from the position of President and Chief Executive Officer of Q-Med AB (publ), with immediate effect. The Board of Directors has appointed Carina Bolin, the company's General Counsel since 2002, as interim CEO.
"We were fortunate to recruit Maria to serve as President and CEO and in this capacity she has created real value for shareholders", comments Anders Milton, Chairman of the Bid Committee[1] and Director of the Board. "We have been able to observe that Maria's leadership, her values and competence have delivered results. Through an increased sales and market focus, Q-Med's position as the leading company within esthetic beauty treatments has been strengthened."
"It feels natural for me to leave now when Galderma is taking over," says Maria Carell. "The role of CEO of a company listed on the stock exchange, for which I was recruited, no longer exists. Q-Med will now be integrated and become the esthetic division of Galderma. Q-Med is a fantastic company with great overall competence and I am proud of what Q-Med's organization has achieved. The merged company has a bright future, of that I am sure," concludes Maria Carell.
Carina Bolin, who will serve in the capacity of interim CEO, joined Q-Med in January 2000 as legal counsel. She has served in the capacity of General Counsel since 2002. Q-Med has applied for delisting of the Company's shares and has announced an Extraordinary General Meeting on March 28, as previously published on March 3, 2011 in a press release.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
